T Cell Epitope-Specific Defects in the Immune Response to Cat Allergen in Patients with Atopic Dermatitis  by Carneiro, Raquel et al.
T Cell Epitope-Speciﬁc Defects in the Immune Response to Cat
Allergen in Patients with Atopic Dermatitis
Raquel Carneiro, Amanda Reefer, Barbara Wilson,w Juergen Hammer,z Thomas Platts-Mills, Natalie
Custis, and Judith Woodfolk
Asthma and Allergic Diseases Center, Department of Internal Medicine and the wDepartment of Dermatology, University of Virginia, Charlottesville, Virginia,
USA; zDepartment of Genomics and Informations Sciences, Hoffman-La Roche, Nutley, New Jersey, USA
Atopic dermatitis (AD) is often associated with high titer IgE antibodies (ab) to allergens, and IL-10-mediated
regulation of IFN-c has been proposed to contribute to this IgE ab production. However, the relevance of IL-10 and
IFN-c to IgE associated with AD has not been examined in the context of an allergen-speciﬁc system. Analysis of
PBMC responses in vitro showed deﬁcient T cell proliferation to overlapping IL-10- (peptide (P) 2:1) and IFN-c-
(P2:2) inducing chain 2 major epitopes of cat allergen (Fel d 1) in cultures from sensitized AD patients (mean IgE to
cat¼ 20.9 IU/ml). Diminished IFN-c induction by Fel d 1 and P2:2, along with elevated peptide-induced IL-10 (except
for P2:1) was observed in PBMC cultures from AD subjects compared with non-AD (sensitized and non-sensitized)
subjects. Neither T cell proliferation nor IFN-c production to chain 2 epitopes could be restored by anti-IL-10 mAb in
cultures from sensitized AD subjects. Moreover, allergen avoidance was associated with a paradoxical decrease in
both IL-10 and IFN-c in peptide-stimulated PBMC from these subjects. Control of IFN-c production to chain 2
epitopes by IL-10 may be relevant to sensitization status. Development of high titer IgE ab in AD could reﬂect a
failure of this mechanism.
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Cytokines elaborated by the Th2 subset of T lymphocytes
govern the production of immunoglobulin E (IgE) antibodies
(ab) by B lymphocytes and eosinophil recruitment to sites of
inflammation, resulting in the development of allergic
disease. Enhanced IgE ab production is a notable feature
of the chronic inflammatory skin disease, atopic dermatitis
(AD) (Ogawa et al, 1971). The presence of high-titer IgE ab
to inhalant allergens, elicitation of an eczematous rash after
application of allergen in an atopy patch test, and improve-
ment of disease during allergen avoidance suggests an
important role for allergen-specific immune responses in the
pathogenesis of AD (Mitchell et al, 1982; Chapman et al,
1983; Tan et al, 1996; Scalabrin et al, 1999; Erwin and
Platts-Mills, 2002). Despite the evidence of Th2 skewing, as
judged by alterations in T helper cell cytokine profiles,
immune mechanisms which govern such changes have
yet to be defined. It has been proposed that elevated
interleukin-10 (IL-10) secretion by monocytes contributes to
T helper cell polarizing events in AD (Lester et al, 1995;
Ohmen et al, 1995; Aiba et al, 2003). Indeed, diminished
interferon (IFN)-g production by T cells from AD patients
does not appear to result from an intrinsic T cell defect per
se since IFN-g production can be restored by co-stimulation
with IL-12 or engagement of CD28 (Jung et al, 1999).
Allergen-reactive T cells derived from patients with AD
are predominantly CD4þ T cells which express the skin-
homing marker, cutaneous lymphocyte-associated antigen
(CLA), suggesting a direct function of these cells in the
disease (Santamaria Babi et al, 1995; Jung et al, 2003).
Despite this, few studies of AD patients have examined T
cell responses in allergen-specific systems. Instead, much
work has focused on phenotypic analysis of T cells isolated
directly from whole blood, or on cells stimulated in vitro
using non-specific stimuli such as phorbol 12-myristate
13-acetate and ionomycin, or anti-CD3 and anti-CD28 mAb
(Sato et al, 1998; Aleksza et al, 2002; Kallstrom et al, 2002;
Okazaki et al, 2002; Simon et al, 2002). The impetus for
such studies may arise from the view that AD reflects an
underlying broad-based defect in immune regulation which
influences the immune response to a multitude of antigens
from diverse sources, including allergens, in a non-specific
manner. However, the recent observation that IL-10 secre-
tion by CD8þ T cells specific for the mite allergen, Der p 1,
is diminished in severe disease suggests that alterations in
allergen-specific T cell- as well as monocyte-derived IL-10
may contribute to disease pathogenesis (Seneviratne et al,
2002).
Definition of the modified Th2 response in individuals
exposed to high-dose cat allergen, Fel d 1, has facilitated
studies on immunologic tolerance induced by natural
exposure to an inhalant allergen. High-titer IgG and IgG4
ab to Fel d 1 in the absence of IgE is the hallmark of the
modified Th2 response (Platts-Mills et al, 2001). Given the
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high titers of IgE ab to Fel d 1 in sensitized patients with AD,
we theorized that this disease represents a ‘‘breakdown of
tolerance’’ which would be evident at the T cell level. Here
we show that major epitopes of Fel d 1 which map to the
amino-terminal region of chain 2 of the molecule selectively
induce high levels of IL-10 or IFN-g. Activation of T cells
which target these epitopes during conventional immu-
notherapy suggests that these epitopes fulfill a regulatory
role (Reefer et al, in press). Since alterations in IL-10 and
IFN-g production have been implicated in AD, we examined
T cell responses to peptides spanning both polypeptide
chains of the Fel d 1 molecule in sensitized patients with
AD. We report that diminished T cell proliferation to chain 2
major epitopes is specifically associated with sensitization
to cats and with disease severity in patients with AD.
Furthermore, chain 2 epitopes stimulate an altered pattern
of IL-10 production and markedly reduced IFN-g in PBMC
cultures from AD patients. In contrast to patients without
AD, Tcell responsiveness to chain 2 epitopes is not restored
by blocking IL-10 in AD subjects with high-titer IgE ab.
These observations are consistent with a role for allergen-
specific T cell dysregulation in AD.
Results
Sensitization to cat allergen in patients with AD is
associated with high-titer antigen-speciﬁc IgE ab Ana-
lysis of serum ab responses to cat showed a significantly
decreased prevalence of the modiﬁed Th2 response to cat
(i.e., IgGposIgEneg) among patients with AD (four of 55)
compared with subjects without AD (14 of 57, p¼0.013)
(Fig 1a). Among those individuals with measurable IgE ab to
cat (40.35 IU per mL), mean titers of IgE were increased in
AD patients (11.2 IU per mL) compared with those without
AD (2.3 IU per mL) (p¼0.001). Furthermore, the prevalence
of high-titer IgE ab (410 IU per mL) was significantly
increased in AD (22 of 40) compared with non-AD (five of 24)
subjects (p¼ 0.009) (Fig 1b). All subsequent studies were
carried out in nine cat-sensitized patients with AD (mean IgE
ab to cat¼20.9 IU per mL) (SþAD), ten non-cat-sensitized
patients with AD (NSþAD), 14 cat-sensitized patients
without AD (mean IgE ab to cat¼4.4 IU per mL) (S), and
11 serum ab-negative subjects (Control). Mean levels of
total IgE were increased in cat-sensitized patients with AD
compared with all other patient groups (po0.004). Further-
more, cat-sensitized patients with AD had markedly
elevated titers of IgE ab to both cat extract and Fel d 1
compared with cat-sensitized patients without AD (po0.01)
(Fig 1c, d). Cat-sensitized patients with AD also showed
increased IgG ab specific for Fel d 1 compared with their
non-sensitized (NS) counterparts (Fig 1d).
Fel d 1 induces an increased ratio of IL-10 to IFN-c
in cultures from AD patients compared with healthy
controls Mean Tcell proliferative responses to Fel d 1 in 6-d
PBMC cultures were moderately decreased in sensitized
AD patients (stimulation index¼ 9) compared with non-
sensitized AD and control subjects (stimulation indices¼ 16
and 14, respectively) (p40.3) (Fig 2a). Analysis of cytokine
profiles showed diminished IFN-g production in both
sensitized AD (p¼0.013) and non-sensitized AD (p¼ 0.027)
patients compared with serum ab-negative controls (Fig 2b).
As a result, the mean ratio of IL-10 to IFN-g was enhanced
in PBMC derived from sensitized AD (IL-10:IFN-g¼63) and
non-sensitized AD (IL-10:IFN-g¼ 25) patients compared with
controls (IL-10:IFN-g¼5) (po0.043). The levels of IL-5 and
IL-13 were consistently low (i.e., o30 pg per mL) in all
cultures whereas no IL-4 was measurable in any cultures.
The endotoxin content of Fel d 1 was high (410,000 EU
per mg Fel d 1) and attempts to remove endotoxin by
conventional methods were unsuccessful (Woodfolk et al,
2000). Thus, IL-10 secretion by monocytes likely contributed
to the cytokine profile observed in cultures containing Fel d
1. Subsequent studies used endotoxin-free synthetic pep-
tides derived from Fel d 1 which were designed as optimal
major histocompatibility complex (MHC) class III ligands,
thereby excluding adjuvant effects of endotoxin on T cell
responses in vitro.
Altered T cell responsiveness to chain 2 major epitopes
of Fel d 1 is associated with AD In order to further study
the response of AD patients to cat allergen, lymphocytes
were cultured in vitro with each of the 20 overlapping
peptides spanning Fel d 1. Peptides mapping to the amino-
termini of Fel d 1 polypeptide chain 1 (P1:2) and chain
2 (P2:1 and P2:2) stimulated strong T cell proliferative
responses in PBMC cultures from sensitized patients
without AD (mean standardized index X2.5) (Fig 3a). No
difference in the pattern of T cell epitope recognition was
observed between sensitized patients without AD and
healthy controls (data not shown). Cultures from sensitized
patients with AD showed diminished T cell proliferation to
P2:1 and P2:2 compared with non-AD patients (p¼0.003);
however, strong proliferation to these epitopes was ob-
served in cultures from AD patients without IgE ab (Fig 3a
and b). In addition to an association with IgE ab, decreased
proliferation to P2:1 and P2:2 was associated with severe
AD (Fig 3c). In contrast to chain 2 peptides, T cell
proliferative responses to the chain 1 peptide, P1:2, were
diminished in both AD groups (po0.05). Thus, T cell
responses to Fel d 1 peptides in sensitized and non-
sensitized patients with AD were distinguished based on
recognition of chain 2, but not chain 1, epitopes.
Peptides 2:1 and 2:2, were identified as promiscuous MHC
class II ligands (see Materials and Methods). Analysis of
cytokines in PBMC cultures from sensitized subjects without
AD showed that production of IL-10 and IFN-g localized to
P2:1 and P2:2, respectively (Fig 4). Cytokine production to
chain 2 epitopes was altered in cultures from AD patients; the
highest levels of IL-10 were induced by P2:3 (not P2:1)
whereas IFN-g production to P2:2 was markedly reduced
regardless of the IgE ab response to Fel d 1 (Fig 5). Levels of
IL-10 to all 20 peptides were increased in sensitized AD
(26.5  2.3 pg per mL (mean  SEM)) and non-sensitized AD
(26.1  3.9 pg per mL) groups compared with sensitized
subjects without AD (17.8  3.2 pg per mL) and controls
(12.3  1.7 pg per mL) (po0.05). However, analysis of the
mean IFN-g production for all 20 peptides showed no
significant difference for AD and non-AD subjects suggesting
that deficient IFN-g production was selective for P2:2. In
keeping with altered recognition of chain 2 epitopes, analysis
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of the pattern of epitope recognition throughout the whole
molecule as judged by the distribution of mean levels of both
IL-10 and IFN-g was significantly different between cat-
sensitized AD patients and controls (po0.003). Surprisingly,
mean levels of IL-5 for all 20 peptides were significantly
decreased in both AD groups (2.24  0.1 and 2.09  0.1 pg
per mL for sensitized and NS subjects, respectively) com-
pared with sensitized subjects without AD (2.95  0.2 pg per
mL) (po0.001) (Fig 5).
Blocking IL-10 fails to restore proliferation and IFN-c
responses to chain 2 epitopes in AD patients with high-
titer IgE ab to cat We next tested whether blocking IL-10
could restore Tcell proliferation and IFN-g production to chain
2 peptides in cultures from AD patients. Donors selected for
study included two non-sensitized and two sensitized
AD patients (#1 through #4, Table I). In Fel d 1-stimulated
cultures, blocking IL-10 using anti-IL-10 mAb induced
increased proliferation and production of IFN-g in all patients,
although the magnitude of the response was diminished in
AD patients with high-titer IgE ab to cat. However, there was
no effect of anti-IL-10 mAb on either proliferation or IFN-g
levels in cultures stimulated with chain 2 peptides from these
patients. This was in contrast to a marked enhancement of T
cell reactivity to chain 2 peptides in non-AD patients (Fig 6).
Allergen avoidance is associated with a rapid decrease
in IL-10 production and a paradoxical decrease in IFN-c
production in AD patients with high-titer IgE ab to cat In
order to examine the association between allergen expo-
sure and Fel d 1-specific T cell responses, cellular res-
ponses were monitored in vitro in two cat-sensitized
patients with AD receiving a complete allergen avoidance
regimen. Both patients had high-titer IgG ab to Fel d 1
(9,968 U per mL (patient #7) and 17,913 U per mL (patient
#8)) and high-titer IgE ab to cat (4100 IU per mL (#7) and
61.7 IU per mL (#8)) (Table I). Assay of floor dust confirmed
the presence of Fel d 1 in each patient’s home (0.56 and
Figure 1
Serum (IgE) (ab) production to cat extract and to Fel d 1 is enhanced in cat-allergic patients with (AD). Levels of total IgE ab and cat-specific
IgE ab (IU per mL measured by CAP assay) along with Fel d 1-specific IgE, IgG, and IgG4 ab (U per mL measured by radioimmunoprecipitation
assay) were assayed in serum. Panels (a) and (b) show titers of IgG ab to Fel d 1 and IgE ab to cat extract, respectively, among AD and non-AD
groups. Subjects with a modified Th2 response were those with IgG ab to Fel d 1 without IgE ab to cat (filled circles). In (c) and (d), IgE ab (total, cat-
specific and Fel d 1-specific), and IgG and IgG4 ab (Fel d 1-specific) titers are shown for each of four groups: (1) cat-sensitized with AD [SþAD]
(n¼ 9), non-cat-sensitized with AD [NSþAD] (n¼10), sensitized without AD [S] (n¼14) and controls (n¼ 11). In (a), (b), and (c) upper and lower
dotted lines represent high titer values and assay cutoffs, respectively. In (d), dotted lines represent cutoff values for IgE and IgG/IgG4 ab assays.
Horizontal bars represent geometric mean values. (po0.05, po0.01).
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1435 mg per g bedroom floor dust for #7 (no cats in home)
and #8 (two cats in home), respectively). Allergen avoidance
of 12-d duration was associated with a modest decrease in
disease severity score in both patients (55.5–36.5 (#7);
42.5–38 (#8)) without any change in serum IgE or IgG ab
titers. The pattern of T cell epitope recognition was highly
consistent during the study period. In contrast, production
of IL-10 and IFN-g to chain 1 and chain 2 epitopes was
Figure2
Fel d 1 induces high IL-10 but diminished IFN-c in
peripheral blood mononuclear cells (PBMC) from atopic
dermatitis (AD) patients. PBMC were stimulated with
10 mg per mL Fel d 1 for 6 d. (a) Proliferation was measured
by [3H] thymidine incorporation (counts per min) and
expressed as mean stimulation indexþSEM. (b) Culture
supernatants were assayed for cytokines and values ex-
pressed as the meanþSEM. No Ag, no antigen. (po0.03).
Figure 3
Diminished proliferation to chain 2 major epitopes of Fel d 1 is associated with IgE ab to cat and severe disease in patients with atopic
dermatitis. Peripheral blood mononuclear cells PBMC were stimulated with each of the 20 Fel d 1 peptides (7.5 mM) for 6 d and proliferation
determined by [3H] thymidine incorporation. Each peptide was assayed in 12 replicate wells. Data (cpm) were then log transformed and
standardized indexes derived. In (a), the mean standardized index  SEM for each peptide is shown for [S], [SþAD], and [NSþAD] groups.
po0.003 for [S] versus [SþAD] groups. (b) Individual data points for P2:1 and P2:2 within each group. Horizontal bars represent the mean
standardized index value for P2:1 and P2:2 in each group. Arrows denote AD patients with severe disease. (po0.05, po0.01). In (c), the mean
standardized indexþSEM for each of the 20 Fel d 1 peptides is shown for patients with severe (n¼ 6), moderate (n¼ 7), and mild (n¼ 6) AD.
po0.05 for P2:1 and P2:2 (moderate vs severe groups) and for P2:7 (moderate vs mild groups). Dotted lines indicate a mean standardized index
value of 1.5. U, unstimulated wells containing no antigen.
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markedly decreased in both patients with significant reduc-
tions in mean levels of IL-10 (#7) or both cytokines (#8) for
all 20 Fel d 1 peptides (Fig 7).
Discussion
The regulatory cytokine, IL-10, has been implicated in the
development of immunologic tolerance to allergens after
high-dose exposure to respiratory or injected allergens
(Bellinghousen et al, 1997; Akdis et al, 1998; Akbari et al,
2001). Paradoxically, increased expression of IL-10 in skin
lesions and increased IL-10 production in circulating cells
has been reported in patients with AD (Ohmen et al, 1995;
Lee et al, 2000; Aleksza et al, 2002; Aiba et al, 2003). Our
findings show that production of IL-10 and IFN-g localize to
major T cell epitopes of Fel d 1 within polypeptide chain 2 in
cultures from patients without AD. This observation is
consistent with the view that a defined region of the Fel d 1
molecule fulfills a regulatory role in the immune response to
cat. Given that high-titer IgE ab to cat in sensitized patients
with AD might reflect an underlying defect in T cell effector
or regulatory function, we analyzed T cell responses to Fel d
1 in patients with AD. Results showed that altered T cell
responsiveness to chain 2 IL-10- and IFN-g-inducing
epitopes was a feature of AD. Specifically, PBMC from AD
patients with high-titer IgE ab and severe disease showed
diminished Tcell proliferation to these epitopes. Furthermore,
in the context of the whole molecule, Tcell responses among
sensitized and non-sensitized patients with AD were distin-
guishable based solely upon differential recognition of P2:1
and P2:2.
Diminished T cell proliferation to chain 2 epitopes in
sensitized AD patients suggests that differences in the
allergen-specific memory T cell repertoire underlie immune
responses associated with different levels of IgE ab
production. It is tempting to speculate that alterations in
the balance between Th1 and regulatory cytokines resulting
from decreased recognition of chain 2 epitopes may
contribute to disease pathogenesis in sensitized patients
with AD. Whether such differences in the T cell repertoire
directly influence IgE ab responses remains to be deter-
mined. Although proliferative responses to chain 2 epitopes
are diminished, our data suggest that chain 2 epitope-
specific T cells are not absent from the repertoire given the
ability for P2:1 and P2:2 to induce T cell responses, albeit in
an altered fashion, in a minority of sensitized AD patients
(e.g., patient #7, Fig 7). It also seems unlikely that anergy
resulting from high-dose exposure to cat allergen is a cause
since removal of a sensitized patient from an environment
containing high levels of Fel d 1 did not restore T cell
proliferation to chain 2 epitopes, despite changes in
cytokine production (patient #8, Fig 7). Nevertheless, anergy
resulting from lack of co-stimulatory signals provided by
Langerhans cells or cytokines present during T cell priming
cannot be excluded (Van Reijsen et al, 1994; Akdis et al,
1996). We propose that differences in the T cell repertoire
associated with AD arise from T cell activation by allergen at
anatomic sites (i.e., the skin) which are distinct from those in
patients without AD (i.e., the respiratory tract). This could
be explained by increased delivery of allergen through the
skin coupled with generation of distinct antigenic deter-
minants within resident antigen presenting cells, such as
Langerhans cells or inflammatory dendritic epidermal cells
(Wollenberg et al, 1996). Selective expansion or inhibition
of T cells with different specificities and effector/regulatory
functions could then ensue in regional lymph nodes. The
observation that T cell proliferation to chain 2 epitopes is
diminished in patients with severe AD is consistent with the
view that increased access of allergen through barrier
defects in the skin may contribute to alterations in the T cell
repertoire.
Despite the failure of proliferation to chain 2 epitopes in
sensitized patients with AD, the altered pattern of cytokine
responses to chain 2 epitopes was consistent among AD
patients, regardless of sensitization status. Interestingly,
peptide 2:3, not P2:1, induced the highest mean levels of IL-
10, whereas the IFN-g-inducing peptide, P2:2, generally
failed to stimulate IFN-g production in either AD group.
Computer analysis of HLA binding motifs identified P2:3 as
a promiscuous ligand capable of binding to multiple MHC
class II molecules. Thus, the ability for this peptide to induce
Figure 4
Production of IL-10 and IFN-c localize to chain 2 epitopes of Fel d 1
in sensitized subjects without AD. Peripheral blood mononuclear
cells PBMC were cultured with peptides (7.5 mM) and culture super-
natants assayed for cytokine content on day 6. Values represent
arithmetic meansþSEM (n¼ 14). U, unstimulated wells containing no
antigen.
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strong IL-10 production in AD patients with diverse HLA-DR
types was not surprising per se. However, given that P2:1
and P2:2 also contained promiscuous epitopes, strong
reactivity to P2:3 in the presence of low cytokine responses
to P2:1 and P2:2 in AD patients cannot be explained by
differences in HLA binding properties.
Increased production of IL-10 to all Fel d 1 peptides (with
the notable exception of P2:1) was evident in AD patients
Figure 5
Altered cytokine responses are specific for chain 2 epitopes of Fel d 1 in patients with AD. PBMC were cultured with Fel d 1 peptides and
culture supernatants assayed for cytokine content on day 6. Values represent geometric means with upper 95% confidence intervals for each of the
four patient groups. Dotted lines represent limit of sensitivity of the assay. For interleukin (IL)-10 production to P2:3, p¼0.027 for [SþAD] versus
[S]; po0.01 for [NSþAD] versus [S] and controls. For IFN-g production to P2:2, po0.01 for [SþAD] versus [S] and controls; p¼ 0.028 for [NSþAD]
versus controls. For IL-13 production to P2:3, po0.03 for [S] versus [SþAD] and [NSþAD]. U, unstimulated wells containing no antigen.
Table I. Characteristics of subjects studied in IL-10 blocking experiments (#1 through #6) and those who received an allergen
avoidance regimen (#7 and #8)
Subject Group IgG to Fel d 1 (U per mL)a IgE to cat (IU per mL)b DRB1c
#1 NSþAD o140 o0.35 NDd
#2 NSþAD 5,918 o0.35 0401 0701
#3 SþAD 3,297 28.5 1401 1501
#4 SþAD 13,151 38.4 0103 0301
#5 Sensitized 338 0.94 0404 1301
#6 Control o140 o0.35 0701 1101
#7 SþAD 9,968 4100 0102 1102
#8 SþAD 17,913 61.7 0404 0801
aMeasured by antigen binding radioimmunoprecipitation assay.
bMeasured by CAP assay.
cAlleles highlighted in bold represent those predicted to bind to one or more of the chain 2 peptides, P2:1, P2:2, P2:3, or P2:4, using the computer
prediction algorithm, TEPITOPE.
dND, not done.
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(Fig 5). It has been proposed that IL-10 from a variety of
cell sources contributes to Th2 skewing in AD (Lester et al,
1995; Ohmen et al, 1995; Aleksza et al, 2002; Aiba et al,
2003). Although diminished production of IFN-g to Fel d 1
and P2:2 in AD patients would be consistent with this
theory, there was no evidence of enhanced IL-5 or IL-13 in
cultures from AD patients. Furthermore, blocking IL-10
failed to increase IFN-g secretion induced in cultures from
sensitized AD patients stimulated with pooled chain 2
peptides. Surprisingly, blocking IL-10 did increase T cell
responses to whole allergen in cultures from these patients
suggesting a selective defect in regulation of the response
to chain 2 peptides. This raises the important question of
whether IL-10 control of IFN-g production to chain 2
epitopes is a determinant of sensitization status. During
allergen avoidance, levels of peptide-induced IL-10 were
significantly diminished for the two cat-sensitized patients
studied suggesting that allergen exposure contributes to
enhanced epitope-specific IL-10 production; however,
these changes were associated with an unexpected
decrease in IFN-g. Taken together, our findings could be
interpreted in two ways: (1) responsiveness to IL-10 is
abnormal in AD patients, despite the high levels produced
(i.e., IL-10 dysregulation); or (2) alternate factors to IL-10
downregulate IFN-g in AD.
Among non-sensitized AD patients, T cell proliferation
and IFN-g secretion were enhanced in the presence of anti-
IL-10 mAb irrespective of whether antigen was present.
Furthermore, T cell proliferation and IFN-g responses in
unstimulated cultures were high in the absence of anti-IL-10
mAb suggesting endogenous T cell or monocyte activation.
Indeed, spontaneous proliferation and cytokine production
by cells derived from AD patients have been reported
(Glinski et al, 1995; Poulsen et al, 1995; Akdis et al, 1999).
Thus, it could be argued that the effects of blocking IL-10 in
these patients are non-specific. This is in contrast to results
obtained for patients without AD (#5 and #6, Fig 6) which
show a marked increase in proliferation and IFN-g in the
presence of anti-IL-10 mAb for cultures containing Fel d 1
and chain 2 peptides.
In relation to the increased levels of IL-10 in unstimulated
cultures derived from AD patients, (Fig 2) it should be
stressed that a variety of cell types, including monocytes,
may produce IL-10 in our culture system. Monocytes likely
contributed to the high levels of IL-10 observed in Fel d 1-
stimulated cultures, by virtue of the potent effects of
endotoxin on this cell type. Furthermore, it could be argued
that the production of high levels of IL-10 in peptide-
stimulated cultures in the absence of T cell proliferation
(patient #8, Fig 7) reflects IL-10 secretion by non-T cells;
however, levels of the Th1 cytokine, IFN-g, were also
measurable in these cultures suggesting that epitope-
specific T cells become activated but that cytokine
production and proliferation are dissociated (Evavold et al,
1991; Woodfolk et al, 2001). Nevertheless, this still does not
exclude secondary effects on in vitro T cell responses
resulting from interactions between non-specifically acti-
vated antigen presenting cells and T cells. All Fel d 1
peptides were determined to be endotoxin-free; thus, IL-10
induction most likely results from antigenic properties of the
Figure 6
Blocking IL-10 fails to restore T cell proliferation and
IFN-c production to chain 2 epitopes in AD patients with
high-titer IgE antibodies (ab) to cat. PBMC from six
donors (two non-sensitized with AD, two sensitized with AD,
one sensitized and one control) were stimulated with Fel d 1
or pooled chain 2 peptides (P2:1, P2:2, P2:3, and P2:4) with
or without 10 mg per mL anti-IL-10 mAb. Proliferation and
cytokine responses were measured on day 7. Proliferation
values represent mean cpm for 12 replicate wellsþSEM.
po0.01. Data are representative of duplicate experiments.
ND, not done.
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peptides themselves. Although a variety of peptides (e.g.,
neuropeptides) are known to induce IL-10 production by
monocytes, the authors are unaware of a mechanism of
direct activation of monocytes by Fel d 1 peptides. Data
which support the view that IL-10 in peptide-stimulated
cultures results primarily from T cell activation includes: (1)
localization of IL-10 induction to chain 2 epitopes containing
multiple putative HLA class II ligands; (2) localization of IL-
10 induction to chain 2 epitopes which induce strong T cell
proliferation; and (3) differences in the pattern of IL-10
responsiveness to chain 2 peptides in patients with and
without AD. This latter observation would be difficult to
explain if non-specific monocyte-derived IL-10 was the
major source of IL-10 in these cultures.
In conclusion, our results support a role for selective
defects in the allergen-specific T cell repertoire associated
with high-titer IgE ab responses. The focus of this
phenomenon on overlapping IL-10- and IFN-g-inducing
peptides of the major cat allergen Fel d 1, implicates
changes in epitope-specific Th1 and/or T regulatory cells in
this process.
Materials and Methods
Subjects Peripheral blood samples were obtained from 112
subjects, including 56 patients with AD who were diagnosed using
the criteria of Hanifin and Rajka (1980). Healthy subjects without
AD (n¼ 57) were recruited by advertisement. Subjects were
classified as cat-sensitized with AD (n¼ 9), non-cat-sensitized
with AD (n¼ 10), cat-sensitized without AD (n¼ 14), and controls
(n¼ 11). Sensitized patients with AD were classified on the basis of
serum IgE ab to cat 40.7 IU per mL measured by CAP assay
(Pharmacia Biotech, Uppsala, Sweden). Sensitized patients with-
out AD were those with both a positive skin prick test (45  5 mm
wheal) to cat extract and serum IgE ab to cat 40.7 IU per mL.
Non-cat-sensitized subjects with AD were those with no measur-
able serum IgE ab to cat (o0.35 IU per mL) with (n¼ 3) or without
(n¼ 7) serum IgG ab to Fel d 1 measured by radioimmunopreci-
pitation assay (Rowntree et al, 1987; Platts-Mills et al, 2001).
Patients with no detectable serum IgE ab to cat extract and without
IgG ab to Fel d 1 were classified as serum ab-negative controls.
Severity of disease was assessed in 19 patients with AD (six
severe, seven moderate, six mild) using the SCORAD index
(Stalder et al, 1993) which combines objective (extent and intensity
of lesions) and subjective (daytime pruritus and sleep loss) criteria.
No patients received systemic immunosuppressive drugs within 6
mo of starting the study. Genotyping for the major HLA allele,
DRB1, was carried out using PCR-based methods previously
described (Woodfolk et al, 2000). Studies on human subjects were
approved by the University of Virginia Human Investigation
Committee and adhered to Declaration of Helsinki Guidelines.
Reagents Natural Fel d 1 was affinity purified from cat hair
(Chapman et al, 1988; De Groot et al, 1988) and labeled with 125I
for use in radioimmunoprecipitation assays. Peptides (14–19
residues in length, n¼ 20) with a 10 amino acid overlap spanning
both polypeptide chains of the Fel d 1 heterodimer (peptides (P)1:1
through P1:9 for chain 1 and P2:1 through P2:11 for chain 2) were
Figure 7
Reduced exposure to cat allergen is
associated with a rapid decrease in
IL-10 production to Fel d 1 peptides
in AD patients with high-titer immuno-
globulin E (IgE) ab to cat. Peptide-
specific T cell proliferation and production
of interleukin (IL)-10 and interferon (IFN)-g
were monitored at day 0 (baseline), day 6,
and day 12, in two cat-sensitized AD
patients receiving a complete allergen
avoidance regimen. Mean changes in IL-
5 or IL-13 at 12 d were not significantly
different from baseline levels. Dotted line
represents a standardized index value of
1.5. Arrows denote the IL-10-inducing
peptide, P2:3. U, unstimulated wells con-
taining no antigen.
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synthesized by standard F-moc chemistry (University of Virginia
Biomolecular Research Facility) using a Symphony automated
peptide synthesizer (50 mM scale; Rainin, Woburn, Massachusetts)
and purified to 490% by reverse phase high-performance liquid
chromatography. Peptides were determined to be endotoxin free
by quantitative chromogenic Limulus Amebocyte Lysate Assay
(BioWhittaker, Walkersville, Maryland). Fel d 1, tetanus toxoid (TT),
and PHA were sterile-filtered prior to use. IL-4 was measured by
ELISA (Pelikine, CLB, Amsterdam, The Netherlands). Matched
mAb pairs for measurement of IL-5, IL-10, IL-13, and IFN-g by
ELISA and anti-IL-10 mAb (rat IgG2a kappa) used in blocking
studies were obtained from Pierce-Endogen (Woburn, Massachu-
setts). Rat IgG2a kappa isotype control was obtained from
Biosource International (Camarillo, California).
Cell cultures PBMC were isolated from 100 mL of peripheral
blood by density gradient centrifugation over Ficoll–Paque
(Pharmacia Biotech) and cultured in RPMI 1640 (Life Technologies,
Gaithersburg, Maryland) supplemented with L-glutamine, 100 U
per mL penicillin, 100 mg per mL streptomycin, and 10% heat-
inactivated autologous human serum. For proliferation assays,
PBMC were cultured in the presence of 10 mg per mL Fel d 1
(2  105 cells in quadruplicate wells) or 7.5 mM Fel d 1-derived
peptides (3  105 cells in 12 replicate wells). TT (10 mg per mL) and
PHA (20 mg per mL) in quadruplicate wells were used as positive
controls and 60 unstimulated wells (12 wells on each assay plate)
were negative controls. Cells were cultured for 6 d at 371C in 96-
well plates, and pulsed with 1 mCi of [3H] thymidine per well during
the final 8 h of culture before harvesting and counting (Topcount
NXT, Packard Bioscience Co., Downers Grove, Illinois). For
cytokine assays, cells were cultured in 24-well plates (4  106
cells per well in 1 mL volume) in the presence of antigen and
culture supernatants were harvested on day 6 and assayed by
ELISA for cytokines. Values were interpolated from standard
curves to a sensitivity of 0.2 pg per mL for IL-4, 2 pg per mL for
IL-5, IFN-g, and IL-13, and 4 pg per mL for IL-10.
Studies using anti-IL-10 monoclonal antibody Freshly isolated
PBMC were stimulated with Fel d 1 (10 mg per mL) or pooled chain
2 peptides (P2:1, P2:2, P2:3, and P2:4, 7.5 mM each) for 7 d, with or
without anti-IL-10 mAb (10 mg per mL). Unstimulated cultures and
cultures containing an isotype control were included as negative
controls. For proliferation assays, cultures incorporated 12
replicate wells (2  105 cells per well in 96-well plates). For
cytokines, assays were carried out in 24-well plates (4  106 cells
per well) and culture supernatants assayed for IFN-g by ELISA.
Computer prediction of CD4þ T cell epitopes using TEPITO-
PE The primary amino acid sequence of Fel d 1 chains 1 and 2
was loaded into the HLA-DR ligand prediction software, TEPITOPE
(Vaccinome, Kearny, New Jersey), to predict promiscuous HLA-DR
ligands (Sturniolo et al, 1999). HLA-DR alleles most frequent in the
caucasian population (0101, 0301, 0401, 0701, 0801, 1101,
1501) were selected and the TEPITOPE prediction threshold was
set at 5%. Peptides binding to three or more different allotypes
were defined as promiscuous.
Allergen avoidance trial Two cat-allergic patients with severe
AD were admitted to the University of Virginia General Clinical
Research Center under a protocol that included complete allergen
avoidance. Tcell responses, serum ab profiles, and disease severity
were monitored at 6-d intervals for 12 d.
Statistical analysis Between-group frequencies of serum ab were
compared using the Pearson w2-square test and mean serum ab
titers were compared between groups using an independent two-
sample Student’s t test. Proliferative responses were expressed as
mean stimulation indexes (Fel d 1) and mean standardized indexes
(peptides) (Woodfolk et al, 2000). Briefly, standardized indexes
were derived by log transformation (Ln) of cpm (in order to account
for variability among peptide-stimulated replicates) and subtraction
of background levels. By this method of analysis, a standardized
index value X1.5 represents a stimulation index calculated by
traditional methods X8. Initial analysis of the pattern of cytokine
induction of Fel d 1 peptides in sensitized subjects without AD was
carried out using arithmetic meansþSEM. Between-group cyto-
kine responses to peptides were compared using geometric
means with 95% confidence intervals in order to account for the
wide variation within each AD group. An independent two-sample
Student’s t test was used to analyze proliferation and cytokine
responses to Fel d 1 and Fel d 1 peptides. One-way ANOVA was
used to compare the mean cytokine level for the sum of all 20
peptides between groups and the distribution of mean levels of
cytokine responses to all 20 peptides was compared by Wilcoxon
matched-pairs signed-ranks test. Proliferation and cytokine re-
sponses before and after allergen avoidance were compared using
a paired two-sample Student’s t test.
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